“Of course, there is considerable evidence of adverse effects to the peritoneal membrane from prolonged glucose exposure, and because icodextrin offers the potential to reduce glucose in the dialysis prescription, the clinical benefit needs to be balanced against studies that have identified a possible inflammatory signal (10).”